Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3-$13.4 Million, Up 29-30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue
MWN-AI** Summary
Sanuwave Health, Inc. announced preliminary revenue figures for Q4 2025, reporting revenues between $13.3 million and $13.4 million. This marks a significant year-over-year increase of 29% to 30% compared to Q4 2024, achieving the highest quarterly revenues in the company’s history. For the entire year of 2025, Sanuwave’s revenue reached an impressive $44.3 million to $44.4 million, reflecting a 36% increase over 2024 and setting a new full-year record for the company.
Morgan Frank, CEO of Sanuwave, expressed satisfaction with the results, emphasizing that the company maintained guidance for both the fourth quarter and the full year as previously indicated in their Q3 2025 earnings. The latter half of 2025 posed challenges, including significant changes in reimbursement rates for skin substitutes and allografts, reshaping the wound care market. Despite these hurdles, Sanuwave proactively sought new partnerships and sales channels, adapting its business model to continue catering to the ongoing demand for advanced wound care solutions.
The positive momentum exemplified in Q4 positions Sanuwave well for future growth, as Frank noted the company's readiness to capitalize on opportunities spurred by these market changes. He expressed pride in the team’s performance and noted that this successful quarter sets a strong foundation for the forthcoming year.
Sanuwave Health specializes in advanced non-invasive directed energy systems for skin repair, wound healing, and regenerative medicine, leveraging FDA-approved technologies. As they prepare for their earnings report in March, stakeholders can expect further insights into the company's strategic positioning and growth prospects.
MWN-AI** Analysis
Sanuwave Health’s announcement of preliminary Q4 2025 revenues between $13.3 million and $13.4 million marks a significant milestone for the company, reflecting a year-over-year increase of approximately 29-30%. This growth is not only a strong indicator of the company's operational proficiency but also highlights its strategic positioning within the advanced wound care market.
The company's full-year revenue projected increase to $44.3-$44.4 million, representing a robust 36% growth from 2024, reinforces the notion that Sanuwave is well-aligned with market demands and trends. CEO Morgan Frank’s remarks suggest an acute awareness of the evolving industry landscape, particularly in light of reimbursement changes that have reshaped the wound care sector. Such dynamic conditions can often present both challenges and opportunities, and Sanuwave appears to have capitalized on the latter by expanding partnerships and adapting its business model effectively.
Investors should be keen on monitoring Sanuwave’s upcoming earnings report in March, which promises further insights into the company’s positioning and strategic initiatives moving forward. The current record levels of revenue indicate not just strong historical performance, but also the potential for sustained growth as Sanuwave continues to enhance its product offerings and reach within the regenerative medicine space.
However, prospective investors should remain cautious regarding the inherent risks associated with the healthcare sector, including regulatory oversight and competition. These factors may significantly influence future performance and should be considered when evaluating Sanuwave as an investment opportunity.
In conclusion, Sanuwave Health’s preliminary revenue figures present a compelling case for potential investment, especially given its adaptive strategies in a changing market. Investors need to stay informed and assess upcoming developments carefully to navigate the risks and seize the opportunities presented by this promising company.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Sanuwave is pleased to announce preliminary revenues of $13.3 million to $13.4 million for the fourth quarter ended December 31, 2025. This represents the highest quarterly revenues in Company history.
Q4 2025 revenue increased between 29% and 30% compared to Q4 2024.
Full Year 2025 revenue increased to $44.3-$44.4 million up 36% vs Full Year 2024. 2025 annual revenues were an all-time record for the Company.
EDEN PRAIRIE, Minn., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of FDA-approved directed energy systems used in advanced wound care, today announced that revenues for the fourth quarter of 2025 are expected to be in the range of $13.3 to $13.4 million, an increase of 29% to 30% over Q4 2024. This number is within the range of guidance given in the Company’s Q3 2025 earnings release issued on November 7, 2025.
“We’re pleased to once more be on guidance and on track for Q4 and for full year 2025,” said CEO Morgan Frank. “As we discussed when releasing Q3, the second half of 2025 was a time of intense transition in the wound care space as reductions to reimbursement rates for skin-substitutes and allografts profoundly reshaped our market. Periods of such rearrangement are always times of opportunity and Sanuwave has been busy acquiring new partners, new sales channels, and adapting its business model for, while times may change, the fact of patients in need of advanced wound care does not. This space has been a bit of a loose ball drill, and loose balls go to the one who sees them first, moves fastest, and wants them most. I am proud to say that our team excelled in all these things this quarter and it feels good to end the year with another record quarter. We look forward to sharing more about how we are positioning ourselves for the year and opportunities to come when we report earnings in March.”
The preliminary revenue results described herein are based on management’s initial analysis of the fourth quarter ended December 31, 2025, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive directed energy systems used in the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave's end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented and FDA approved/cleared energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
FAQ**
What specific strategies is Sanuwave Health Inc SNWV implementing to navigate the significant changes in reimbursement rates for skin substitutes and allografts that are reshaping the wound care market?
Can Sanuwave Health Inc SNWV provide more insights into the new partners and sales channels acquired in 2025, and how they contributed to the record quarterly revenues?
What factors contributed to the 29% to 30% revenue increase in Q4 2025 for Sanuwave Health Inc SNWV, and how do these factors compare to previous quarters?
How does Sanuwave Health Inc SNWV plan to sustain its growth trajectory in 2026 and beyond, considering the evolving dynamics of the advanced wound care industry?
**MWN-AI FAQ is based on asking OpenAI questions about Sanuwave Health Inc (OTC: SNWV).
NASDAQ: SNWV
SNWV Trading
7.94% G/L:
$31.50 Last:
18,239 Volume:
$29 Open:
